ID: ALA3822488

Max Phase: Preclinical

Molecular Formula: C23H26F2N4O4S

Molecular Weight: 492.55

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)(OC(=O)N1CCC(n2ncc3cc(-c4ccc(S(C)(=O)=O)cc4)ncc32)CC1)C(F)F

Standard InChI:  InChI=1S/C23H26F2N4O4S/c1-23(2,21(24)25)33-22(30)28-10-8-17(9-11-28)29-20-14-26-19(12-16(20)13-27-29)15-4-6-18(7-5-15)34(3,31)32/h4-7,12-14,17,21H,8-11H2,1-3H3

Standard InChI Key:  CYZKSRYMGPWAQR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 492.55

Molecular Weight (Monoisotopic): 492.1643

AlogP: 4.32

#Rotatable Bonds: 5

Polar Surface Area: 94.39

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 1.97

CX LogP: 2.11

CX LogD: 2.11

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.53

Np Likeness Score: -1.36

References

1. Matsuda D, Kobashi Y, Mikami A, Kawamura M, Shiozawa F, Kawabe K, Hamada M, Oda K, Nishimoto S, Kimura K, Miyoshi M, Takayama N, Kakinuma H, Ohtake N..  (2016)  Design and synthesis of 1H-pyrazolo[3,4-c]pyridine derivatives as a novel structural class of potent GPR119 agonists.,  26  (15): [PMID:27390068] [10.1016/j.bmcl.2016.06.050]

2. Matsuda D, Kobashi Y, Mikami A, Kawamura M, Shiozawa F, Kawabe K, Hamada M, Nishimoto S, Kimura K, Miyoshi M, Takayama N, Kakinuma H, Ohtake N..  (2017)  Novel 3H-[1,2,3]triazolo[4,5-c]pyridine derivatives as GPR119 agonists: Synthesis and structure-activity/solubility relationships.,  25  (16): [PMID:28662959] [10.1016/j.bmc.2017.06.014]

Source

Source(1):

• Scientific Literature